Contact
searchSearch
HMP Global
Login

News

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
News
Updated IMproveMF Protocol Advances Imetelstat Plus Ruxolitinib Into Phase 1b in Frontline Myelofibrosis
07/08/2026
Stephanie Holland
Results from an updated protocol presented at the ASCO Annual Meeting describe the phase 1b expansion of the IMproveMF trial, which is evaluating imetelstat plus ruxolitinib as frontline therapy for patients with intermediate- or high-risk...
Results from an updated protocol presented at the ASCO Annual Meeting describe the phase 1b expansion of the IMproveMF trial, which is evaluating imetelstat plus ruxolitinib as frontline therapy for patients with intermediate- or high-risk...
Results from an updated protocol...
07/08/2026
Oncology
FDA Approval
FDA Approves Extended-Release Ruxolitinib Across Hematologic Indications
05/07/2026
Stephanie Holland
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic bioequivalence data, the FDA has approved extended-release ruxolitinib for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease.
Based on pharmacokinetic...
05/07/2026
Oncology
News
High Non-Relapse Mortality Remains Barrier to Allogeneic Transplantation Success Rates for Patients With Myelofibrosis
01/14/2026
Emily Estrada
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality.
Among patients with...
01/14/2026
Oncology
News
Pacritinib Therapy Shows Improved Symptom Reduction and Spleen Response for Patients With Myelofibrosis and Thrombocytopenia
01/14/2026
Emily Estrada
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and...
Pacritinib therapy showed...
01/14/2026
Oncology
Ciro Rinaldi, MD, PhD
Conference Coverage
Elritercept Plus Ruxolitinib Demonstrates Favorable Safety and Strong Efficacy for Patients With Myelofibrosis and Anemia: RESTORE Trial
01/14/2026
Ciro Rinaldi, MD, PhD
Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.
Ciro Rinaldi, MD, PhD, shared results from the phase 2 RESTORE trial, which evaluated the combination of elritercept and ruxolitinib among patients with myelofibrosis and anemia who were resistant or intolerant to ruxolitinib alone.
Ciro Rinaldi, MD, PhD, shared...
01/14/2026
Oncology
Andrew Kuykendall, MD
Conference Coverage
Rusfertide Demonstrates Durable Hematocrit Control and Symptom Improvement for Polycythemia Vera: VERIFY Trial
12/17/2025
Andrew Kuykendall
At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.
At the 2025 ASH Annual Meeting & Exposition, Andrew Kuykendall, MD, discussed updated results from the phase 3 VERIFY trial which evaluated rusfertide among patients with polycythemia vera.
At the 2025 ASH Annual Meeting &...
12/17/2025
Oncology
News
Ruxolitinib Therapy for Myelofibrosis Demonstrates Comparable Efficacy and Safety Among All Patient Age Groups
12/01/2025
Emily Estrada
According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.
According to a retrospective analysis, ruxolitinib therapy for patients with myelofibrosis demonstrated comparable efficacy across all age groups.
According to a retrospective...
12/01/2025
Oncology
News
Rovadicitinib Shows Efficacy and Manageable Safety for Ruxolitinib-Resistant or Intolerant Myelofibrosis
10/28/2025
Emily Estrada
Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.
Among patients with myelofibrosis refractory or intolerant to ruxolitinib, the JAK/ROCK inhibitor rovadicitinib demonstrated promising clinical activity and safety in early clinical trials.
Among patients with...
10/28/2025
Oncology

Recent News

FDA Approval
FDA Approves and Launches Generic Lanreotide Injection Referencing Somatuline Depot
09/23/2026
Stephanie Holland
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s lanreotide injection referencing Somatuline Depot for acromegaly, advanced gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome, expanding availability of the long-acting somatostatin analog across...
The FDA approved Amneal’s...
09/23/2026
Oncology
News
NHS-Galleri Trial Finds No Significant Reduction in Stage III or IV Cancer With Multicancer Blood Screening
09/23/2026
Stephanie Holland
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized NHS-Galleri trial showed that adding blood-based multicancer early-detection testing to usual care did not significantly reduce the incidence of late-stage cancers compared with usual care alone, although fewer...
Results from the randomized...
09/23/2026
Oncology
News
NCCN Recommends Rusfertide as Category 1 Option Across Low- and High-Risk Polycythemia Vera
09/22/2026
Stephanie Holland
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines recommend rusfertide as a Category 1 treatment option across low- and high-risk polycythemia vera, incorporating the first-in-class hepcidin mimetic into clinical management following findings demonstrating hematocrit...
Updated NCCN Guidelines...
09/22/2026
Oncology
News
FDA Grants Fast Track Designation to LYT-200 Plus Hypomethylating Therapy for Relapsed or Refractory High-Risk Myelodysplastic Syndromes
09/22/2026
Emily Estrada
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track designation to LYT-200 plus a hypomethylating agent for relapsed or refractory high-risk myelodysplastic syndromes following early-phase findings demonstrating clinical activity and supporting advancement of the...
The FDA granted Fast Track...
09/22/2026
Oncology
News
Trastuzumab Deruxtecan Reduces Risk of Progression or Death in First-Line HER2-Mutant Non-Small Cell Lung Cancer
09/22/2026
Stephanie Holland
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3 DESTINY-Lung04 trial demonstrated that first-line trastuzumab deruxtecan significantly improved progression-free survival and response compared with pembrolizumab plus chemotherapy in advanced HER2-mutant non-small...
Results from the phase 3...
09/22/2026
Oncology
News
Tafasitamab Plus Lenalidomide and R-CHOP Significantly Improves PFS in High-Risk Diffuse Large B-Cell Lymphoma or High-Grade B-Cell Lymphoma
09/21/2026
Emily Estrada
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3 FrontMIND trial demonstrated that adding tafasitamab and lenalidomide to R-CHOP significantly improved progression-free survival in previously untreated patients with high-risk diffuse large B-cell lymphoma or...
Results from the phase 3...
09/21/2026
Oncology
FDA Approval
FDA Approves Imlunestrant Plus Abemaciclib for ESR1-Mutated Advanced Breast Cancer
09/18/2026
Stephanie Holland
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase 3 EMBER-3 trial, the FDA approved imlunestrant plus abemaciclib for previously treated ESR1-mutated, ER-positive, HER2-negative advanced or metastatic breast cancer, establishing a biomarker-selected...
Based on results from the phase...
09/18/2026
Oncology
FDA Alerts
FDA Approves Taletrectinib Label Update Reflecting Durable Responses in TKI-Naïve ROS1-Positive Non-Small Cell Lung Cancer
09/17/2026
Emily Estrada
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental new drug application updating the taletrectinib label with longer-term TRUST-I data demonstrating sustained response durability in TKI-naïve advanced ROS1-positive non-small cell lung cancer, with no new safety...
The FDA approved a supplemental...
09/17/2026
Oncology
News
Epcoritamab Plus Lenalidomide and Rituximab Shows Superior Efficacy in Second-Line or Later Follicular Lymphoma
09/17/2026
Emily Estrada
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE FL-1 trial demonstrated that adding epcoritamab to lenalidomide plus rituximab significantly improved response, depth of response, and progression-free survival in patients with relapsed or refractory...
Results from the phase 3 EPCORE...
09/17/2026
Oncology
News
Low-Dose Ruxolitinib Significantly Reduces Acute Graft-Versus-Host Disease After Haploidentical Transplantation
09/17/2026
Emily Estrada
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial demonstrated that replacing mycophenolate mofetil with low-dose ruxolitinib significantly reduced acute graft-versus-host disease following haploidentical hematopoietic stem-cell transplantation, supporting...
Results from a phase 3 trial...
09/17/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use